WA
The startup develops immune-anticancer drugs utilizing an antibody-drug conjugate (ADC) linker platform technology to enhance the efficacy of cancer treatments. This approach accelerates the drug development process for researchers and medical practitioners, addressing the urgent need for more effective cancer therapies.
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup develops immune-anticancer drugs utilizing an antibody-drug conjugate (ADC) linker platform technology to enhance the efficacy of cancer treatments. This approach accelerates the drug development process for researchers and medical practitioners, addressing the urgent need for more effective cancer therapies.